TrialNature communications2024

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.

Jorge Gómez Tejeda Zañudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.